Logo image of AMS

AMERICAN SHARED HOSPITAL SER (AMS) Stock Fundamental Analysis

NYSEARCA:AMS - US0295951059 - Common Stock

2.5 USD
+0.08 (+3.31%)
Last: 9/11/2025, 12:32:36 PM
Fundamental Rating

3

AMS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. While AMS is still in line with the averages on profitability rating, there are concerns on its financial health. AMS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year AMS has reported negative net income.
AMS had a positive operating cash flow in the past year.
AMS had positive earnings in 4 of the past 5 years.
AMS had a positive operating cash flow in each of the past 5 years.
AMS Yearly Net Income VS EBIT VS OCF VS FCFAMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

1.2 Ratios

AMS has a better Return On Assets (2.28%) than 60.40% of its industry peers.
Looking at the Return On Equity, with a value of 5.85%, AMS is in the better half of the industry, outperforming 63.37% of the companies in the same industry.
The Return On Invested Capital of AMS (0.97%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for AMS is below the industry average of 9.19%.
Industry RankSector Rank
ROA 2.28%
ROE 5.85%
ROIC 0.97%
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)4.67%
ROIC(5y)N/A
AMS Yearly ROA, ROE, ROICAMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

With a decent Profit Margin value of 4.93%, AMS is doing good in the industry, outperforming 77.23% of the companies in the same industry.
AMS's Profit Margin has improved in the last couple of years.
AMS has a Operating Margin (2.22%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of AMS has declined.
With a Gross Margin value of 27.31%, AMS perfoms like the industry average, outperforming 54.46% of the companies in the same industry.
In the last couple of years the Gross Margin of AMS has remained more or less at the same level.
Industry RankSector Rank
OM 2.22%
PM (TTM) 4.93%
GM 27.31%
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
AMS Yearly Profit, Operating, Gross MarginsAMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AMS is destroying value.
The number of shares outstanding for AMS has been increased compared to 1 year ago.
Compared to 5 years ago, AMS has more shares outstanding
The debt/assets ratio for AMS is higher compared to a year ago.
AMS Yearly Shares OutstandingAMS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
AMS Yearly Total Debt VS Total AssetsAMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 1.06, we must say that AMS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.06, AMS is doing worse than 68.32% of the companies in the same industry.
A Debt/Equity ratio of 0.76 indicates that AMS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.76, AMS is in line with its industry, outperforming 45.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Altman-Z 1.06
ROIC/WACC0.11
WACC9.24%
AMS Yearly LT Debt VS Equity VS FCFAMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

AMS has a Current Ratio of 1.87. This is a normal value and indicates that AMS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.87, AMS is in the better half of the industry, outperforming 69.31% of the companies in the same industry.
A Quick Ratio of 1.87 indicates that AMS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.87, AMS is in the better half of the industry, outperforming 72.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.87
AMS Yearly Current Assets VS Current LiabilitesAMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2

3. Growth

3.1 Past

AMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -511.11%.
AMS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.28% yearly.
The Revenue has grown by 32.90% in the past year. This is a very strong growth!
AMS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.58% yearly.
EPS 1Y (TTM)-511.11%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%-300%
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%0.21%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.5%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.31%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMS Yearly Revenue VS EstimatesAMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
AMS Yearly EPS VS EstimatesAMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 0 0.2 -0.2 0.4

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMS Price Earnings VS Forward Price EarningsAMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

98.02% of the companies in the same industry are more expensive than AMS, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.52
AMS Per share dataAMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for AMS!.
Industry RankSector Rank
Dividend Yield N/A

AMERICAN SHARED HOSPITAL SER

NYSEARCA:AMS (9/11/2025, 12:32:36 PM)

2.5

+0.08 (+3.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11
Inst Owners13.91%
Inst Owner Change-4.84%
Ins Owners34.16%
Ins Owner Change4.75%
Market Cap16.27M
Analysts80
Price Target4.59 (83.6%)
Short Float %1.42%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1039.6%
Min EPS beat(2)-2080.2%
Max EPS beat(2)0.99%
EPS beat(4)1
Avg EPS beat(4)-582.62%
Min EPS beat(4)-2080.2%
Max EPS beat(4)0.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.83%
Min Revenue beat(2)-0.96%
Max Revenue beat(2)16.61%
Revenue beat(4)2
Avg Revenue beat(4)5.32%
Min Revenue beat(4)-7.97%
Max Revenue beat(4)16.61%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.22%
PT rev (3m)-7.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-173.33%
EPS NY rev (3m)-173.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-4.44%
Revenue NY rev (3m)-15.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF 3.59
P/B 0.66
P/tB 0.7
EV/EBITDA 3.52
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)0.7
OCFY27.86%
SpS4.49
BVpS3.79
TBVpS3.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.28%
ROE 5.85%
ROCE 1.28%
ROIC 0.97%
ROICexc 1.24%
ROICexgc 1.28%
OM 2.22%
PM (TTM) 4.93%
GM 27.31%
FCFM N/A
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)4.67%
ROIC(5y)N/A
ROICexc(3y)6.77%
ROICexc(5y)N/A
ROICexgc(3y)7.11%
ROICexgc(5y)N/A
ROCE(3y)6.05%
ROCE(5y)N/A
ROICexcg growth 3Y-13.43%
ROICexcg growth 5Y-5.81%
ROICexc growth 3Y-13.18%
ROICexc growth 5Y-6.48%
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Debt/EBITDA 2.71
Cap/Depr 171.25%
Cap/Sales 36.84%
Interest Coverage 0.43
Cash Conversion 65.37%
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.87
Altman-Z 1.06
F-Score5
WACC9.24%
ROIC/WACC0.11
Cap/Depr(3y)86.06%
Cap/Depr(5y)59.68%
Cap/Sales(3y)19.8%
Cap/Sales(5y)14.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-511.11%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%-300%
EPS Next Y49.5%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%0.21%
Revenue Next Year9.31%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-70.81%
EBIT growth 3Y-6.85%
EBIT growth 5Y-9.07%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-175.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.11%
OCF growth 3Y-70.14%
OCF growth 5Y-53.93%